These are the stocks posting the largest moves before the bell.Market Insiderread more
More and more American firms are calling for the Trump administration to resolve its conflict with China.World Economyread more
The Fed is not likely to make a move on interest rates when it meets this week, but it should clear the way for a rate cut later in the summer.Market Insiderread more
American Airlines will become first U.S. airline to order new Airbus A321XLR, according to a source familiar with details of the agreement.Paris Air Showread more
Facebook's new cryptocurrency project, titled Libra and backed by the likes of Visa and Booking Holdings, is being widely embraced by market watchers.Trading Nationread more
Huawei CEO Ren Zhengfei tells CNBC the company's business is still strong in China.Technologyread more
U.S. President Donald Trump officially kicked off his reelection campaign Tuesday at a Florida rally where he exhorted thousands of rollicking supporters to keep advancing his...Politicsread more
But BlackRock's global fixed income chief also says he doesn't think the Fed will announce a rate cut until July.Market Insiderread more
As Beijing has raised duties in response to the Trump administration's spate of tariff announcements, it also lowered trade barriers for exporters around the world.Marketsread more
Global watchdogs and top U.S. Congress members are calling for oversight of a digital asset being launched by Facebook and roughly two dozen other stakeholders.Marketsread more
Mortgage applications were down 3.4% from the previous week, but still up 31.6% from a year earlier, according to the Mortgage Bankers Association.Real Estateread more
As Wall Street becomes gripped by the drama of Valeant — the drug company that has been under assault from both short sellers and Washington's war on drug prices — Jim Cramer would like to finally acknowledge that not every drug company roll-up is like Valeant.
Horizon Pharma is a $3.5 billion roll-up company. Roll-ups gain most of their growth through making a series of acquisitions. And while the company only has a market cap of $3.5 billion, significantly smaller than Valeant, its stock has been trading like a miniature version of Valeant.
When Horizon Pharma reported on Friday, it blew away the numbers. The company has seven drugs on the market that target unmet needs in pain, rheumatology and rare orphan diseases. It reported a stellar 34-cent earnings beat from a 40-cent basis, and management provided spectacular full-year guidance.
Best of all, Horizon was able to generate these numbers without a ridiculous price hike. The main driver was doctors writing more prescriptions for its drugs. Meaning, its growth is organic and seemingly sustainable.
"I wouldn't be at all surprised if this stock has a lot more room to run, because it's been severely underestimated by the market," the "Mad Money " host said.
Cramer spoke with Horizon Pharma CEO Timothy Walbert, who explained that the pharmacies Horizon works with all have one key goal — the doctor writes a prescription for its medicine because it has a clinical benefit, and the pharmacy ensures that the patient gets it. Horizon has cut out the middle men who receive a financial incentive.
"Our role is to ensure that the patient gets what the doctor intended," Walbert said. (Tweet This)
Read more from Mad Money with Jim Cramer
The CEO also added that if there is commercial coverage, Horizon will work with the copay to ensure that the patient receives medicine for less than $10. Currently, 96 percent of patients are paying less than $10. In the event that a managed care plan rejects the medication, Horizon will provide the medicine for free to the patient.
Going forward, Walbert said that the heat in the pharmaceutical industry will not prevent it from buying additional companies.
"We've got the capacity to finance the transactions; we've guided that we are going to announce at least one to two incremental transactions this year and two to five on an ongoing basis each year from now to 2020, based on our long-range plan," Walbert added.